MedTrace Logo

Double Immunosuppression With or Without Anti-fibrotic in Scleroderma ILD

NCT07491523 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 35

Last updated 2026-03-24

No results posted yet for this study

Summary

Patients with ssc-ild receiving double immunosuppression with or without anti fibrotic tratment

Conditions

  • SSc-Systemic Sclerosis

Interventions

DRUG

Antifibrotic drugs (nidanib or pirfenidone)

Ssc - ild

DRUG

MMF Immunosuppression

we will compare patients with SSc-ILD taking RTX and mmf and patients that are taking RTX,mmf and nintedanib

Sponsors & Collaborators

  • University of Patras

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-01
Primary Completion
2026-07-31
Completion
2027-03-31
FDA Drug
Yes

Countries

  • Greece

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07491523 on ClinicalTrials.gov